Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Phase 1 Trial
Recent news which mentions Phase 1 Trial
< Previous
1
2
3
4
5
6
7
8
Next >
Sigilon Therapeutics Issues An Update On Its Early-Stage Hemophilia Study
November 29, 2021
Tickers
SGTX
Tags
Hemophilia A
General
Benzinga
From
Benzinga
Selecta's Gene Therapy Trial For Genetic Metabolic Disorder Put On FDA Hold
November 26, 2021
Tickers
SELB
Tags
gene therapy
General
SELB
From
Benzinga
See Why FDA Hit Red Light On Kura's Early-Stage Leukemia Trial
November 24, 2021
Tickers
KURA
Tags
Benzinga
Short Ideas
Small Cap
From
Benzinga
Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial
November 23, 2021
Tickers
APVO
Tags
Benzinga
Health Care
Trading Ideas
From
Benzinga
Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose
November 22, 2021
Tickers
AFMD
Tags
Movers
Phase 2 Trial
Trading Ideas
From
Benzinga
Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why
November 19, 2021
Tickers
DRMA
Tags
Penny Stocks
Biotech
Phase 1 Trial
From
Benzinga
Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer
November 19, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Non/Small Cell Lung Cancer
Health Care
Briefs
From
Benzinga
Safety Signals Force Enanta To Stop EDP-721 HBV Program
November 19, 2021
Tickers
ENTA
Tags
Small Cap
General
Benzinga
From
Benzinga
Plus Therapeutics' Targeted Radiotherapy Shows Encouraging Overall Survival In Brain Tumour Trial
November 18, 2021
Tickers
PSTV
Tags
Biotech
Penny Stocks
General
From
Benzinga
Spark Therapeutics' Hemophilia Gene Therapy Shows Reduction In Bleeding Episodes
November 18, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Benzinga
RHHVF
Briefs
From
Benzinga
Codiak BioSciences' Exosome Candidate Shows Tumor Shrinkage In Early Study
November 16, 2021
Tickers
CDAK
Tags
Biotech
Solid Tumor
General
From
Benzinga
Rocket Pharma To Test Lower Dose Of Gene Therapy In Genetic Disorder Trial
November 15, 2021
Tickers
RCKT
Tags
Health Care
Trading Ideas
Briefs
From
Benzinga
Why Are EyePoint Shares Trading Higher Today?
November 15, 2021
Tickers
EYPT
Tags
Long Ideas
Market News
why it's moving
From
Benzinga
Moderna Posts Interim Data From mRNA Triplet Program In Solid Tumors
November 15, 2021
Tickers
AZN
MRNA
Tags
Solid Tumor
General
Benzinga
From
Benzinga
Why Did Oncorus Shares Slump To 52-Week Low Today?
November 12, 2021
Tickers
ONCR
Tags
Briefs
Trading Ideas
Health Care
From
Benzinga
Agenus Posts Early Data For CTLA-4 Drug Candidate Across Tumor Types
November 12, 2021
Tickers
AGEN
Tags
AGEN
Small Cap
Benzinga
From
Benzinga
Why Did Mizuho Upgrade This Biotech Stock Focused On Age-Related Eye Diseases?
November 10, 2021
Tickers
UBX
Tags
UBX
Upgrades
Movers
From
Benzinga
Freeline Therapeutics Touts Encouraging Data From Fabry Disease Program
November 10, 2021
Tickers
FRLN
Tags
Phase 2 Trial
Penny Stocks
Biotech
From
Benzinga
Yumanity Therapeutics Stock Plunges After Parkinson's Trial Data
November 10, 2021
Tickers
YMTX
Tags
Health Care
Trading Ideas
Briefs
From
Benzinga
Terns' Potential NASH Candidate Shows Potent Liver Target Engagement
November 10, 2021
Tickers
TERN
Tags
Benzinga
Non Alcoholic steatohepatitis
Trading Ideas
From
Benzinga
Takeda, Shattuck Labs Terminate Immuno-Oncology Pact
November 09, 2021
Tickers
STTK
TAK
TKPHF
Tags
Contracts
News
Phase 1 Trial
From
Benzinga
ALX Oncology Falls After Updated Data For Solid Tumors Candidate
November 09, 2021
Tickers
ALXO
MRK
RHHBF
RHHBY
Tags
RHHVF
MRK
Benzinga
From
Benzinga
Mirati Posts More Responses For Adagrasib-Keytruda Combo In Lung Cancer Setting
November 09, 2021
Tickers
MRK
MRTX
Tags
MRK
Benzinga
Non/Small Cell Lung Cancer
From
Benzinga
MorphoSys Presents Early Felzartamab Data From Autoimmune Kidney Disease Trial
November 05, 2021
Tickers
IMAB
MOR
Tags
Biotech
MOR
Phase 1 Trial
From
Benzinga
Why Did Sangamo Stock Jump 20% Today?
November 04, 2021
Tickers
SGMO
Tags
Biotech
General
Fabry disease
From
Benzinga
Moderna Scraps mRNA-Based Antibody Program Targeting Chikungunya Virus
November 04, 2021
Tickers
MRNA
Tags
Benzinga
Movers
Briefs
From
Benzinga
Equillium Reveals Early Safety Data For Itolizumab In Lupus Patients
November 02, 2021
Tickers
EQ
Tags
Systemic Lupus Erythematosus
Briefs
Biotech
From
Benzinga
Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19
November 01, 2021
Tickers
COCP
Tags
General
Long Ideas
Market News
From
Benzinga
Cabaletta Posts Cell Therapy Data From Third Cohort Of Autoimmune Skin Disorder Trial
November 01, 2021
Tickers
CABA
Tags
News
Phase 1 Trial
cell therapy
From
Benzinga
Calithera Posts Early-Data For Arginase Inhibitor In Cystic Fibrosis Trial
November 01, 2021
Tickers
CALA
Tags
Benzinga
Cystic Fibrosis
Movers
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.